Citations

Showing 10 of 108119 citations.

Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer—It Is Complicated
Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S , Tran, Nguyen H.

Mayo Clinic

JAMA Network Open | November 15, 2021 | Volume: 4 | Issue: 11 | Pages: e2134458

10.1001/jamanetworkopen.2021.34458 | PMID 34779853 Get It

Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study
Usón, Pedro Luiz Serrano , Kunze, Katie L. , Golafshar, Michael A. , Riegert-Johnson, Douglas, Boardman, Lisa A. , Borad, Mitesh J., Ahn, Daniel, Sonbol, Mohamad B., Faigel, Douglas O., Fukami, Norio , Pannala, Rahul, Barrus, Kathleen , Mountjoy, Luke, Esplin, Edward D. , Nussbaum, Robert L., Stewart, A. Keith, Bekaii-Saab, Tanios, Samadder, N. Jewel, Bekaii‐Saab, Tanios , Uson, Pedro L S , Boardman, Lisa , Golafshar, Michael , Esplin, Edward D , Fukami, Norio , Bekaii-Saab, Tanios S , Kunze, Katie L , Riegert-Johnson, Douglas, Borad, Mitesh J., Ahn, Daniel, Sonbol, Mohamad B., Faigel, Douglas O., Pannala, Rahul, Barrus, Kathleen , Mountjoy, Luke, Nussbaum, Robert L., Stewart, A. Keith, Samadder, N. Jewel

Mayo Clinic

Cancer Prevention Research | November 15, 2021 | Volume: 15 | Issue: 2 | Pages: 121-128

10.1158/1940-6207.capr-21-0189 | PMID 34782326 Get It

Abstract Data from germline testing in unselected patients with hepatobiliary cancers are limited. Identification of germline predisposition can have important implications on cancer treatment and family counseling. To determine prevalence of pathogenic germline variants (PGV) in patients with hepatobiliary cancer, we undertook a prospective multi-site study of germline sequencing using a >80-gene next-generation sequencing platform among patients with hepatobiliary cancers receiving care at Mayo Clinic Cancer Centers between April 1, 2018 and March 31, 2020. Patients were not selected on the basis of stage, family cancer history, ethnicity, or age. Family cascade testing was offered at no cost. Of 205 patients, the median age was 65 years, 58.5% were male, 81% were White, and 64.4% had cholangiocarcinoma, 21.5% hepatocellular carcinoma, 7.8% gallbladder cancer, and 4.3% carcinoma of ampulla of Vater. PGV were found in 15.6% (n = 32) of patients, including 23 (71%) in moderate and high penetrance cancer susceptibility genes. A total of 75% of patients with a positive result would not have been detected using guidelines for genetic evaluation. Prevalence of PGV was 15.7% in intrahepatic cholangiocarcinoma, 17% in extrahepatic cholangiocarcinoma, 15.9% in hepatocellular cancer, and 33% in carcinoma of ampulla of Vater. On the basis of these genetic findings, 55% were potentially eligible for approved precision therapy and/or clinical treatment trials. Universal multi-gene panel testing in hepatobiliary cancers was associated with detection of heritable mutations in over 15% of patients most of whom would not have been tested using current guidelines. Germline testing should be considered in all patients with hepatobiliary cancers. Prevention Relevance: Universal multi-gene testing in hepatobiliary cancers was associated with heritable mutations in over 15% of patients, most of whom would not have been tested using current guidelines. 55% were potentially eligible for approved precision therapy and/or clinical treatment trials. Germline testing should be considered in all patients with hepatobiliary cancers.
Targeted Detection of SARS-CoV-2 Nucleocapsid Sequence Variants by Mass Spectrometric Analysis of Tryptic Peptides
Maus, Anthony , Renuse, Santosh , Kemp, Jennifer, Madugundu, Anil K. , Vanderboom, Patrick M. , Blommel, Joseph H. , Jerde, Calvin R. , Dasari, Surendra , Kipp, Benjamin R. , Grebe, Stefan K. , Pandey, Akhilesh , Blommel, Joseph, Jerde, Calvin, Pandey, Akhilesh , Pandey, Akhilesh , Maus, Anthony D , Singh, Ravinder J.

Mayo Clinic

Journal of Proteome Research | November 15, 2021 | Volume: 21 | Issue: 1 | Pages: 142-150

10.1021/acs.jproteome.1c00613 | PMID 34779632 Get It

Large cell calcifying Sertoli cell tumour: a contemporary multi‐institutional case series highlighting the diagnostic utility of PRKAR1A immunohistochemistry
Anderson, William J. , Gordetsky, Jennifer , Idrees, Muhammad T. , Al‐Obaidy, Khaleel I. , Kao, Chia‐Sui , Cornejo, Kristine M. , Wobker, Sara E. , Cheville, John C. , Vargas, Sara O. , Fletcher, Christopher D.�M. , Hirsch, Michelle S. , Gordetsky, Jennifer B , Acosta, Andrés M , Al-Obaidy, Khaleel , Acosta, Andrés

Mayo Clinic

Histopathology | November 15, 2021 | Volume: 80 | Issue: 4 | Pages: 677-685

10.1111/his.14599 | PMID 34780072 Get It

AimsLarge cell calcifying Sertoli cell tumour (LCCSCT) is a rare testicular sex cord‐stromal tumour that primarily affects young patients and is associated with Carney complex. We sought to characterise the clinicopathological features of a series of LCCSCT and evaluate the diagnostic utility of PRKAR1A immunohistochemistry (IHC).Methods and resultsThe LCCSCT cohort (n = 15) had a median age of 16 years (range = 2–30 years). Four patients were known to have Carney complex. PRKAR1A IHC was performed in each case. For comparison, PRKAR1A IHC was also assessed in other sex cord‐stromal tumours, including Sertoli cell tumour, not otherwise specified (SCT, NOS; n = 10), intratubular large cell hyalinising Sertoli cell tumour (n = 1) and Leydig cell tumour (n = 23). Loss of cytoplasmic PRKAR1A expression was observed in all but one LCCSCT (14 of 15; 93%). PRKAR1A expression was retained in all SCTs, NOS (10 of 10; 100%), the majority of Leydig cell tumours (22 of 23; 96%) and an intratubular large cell hyalinising Sertoli cell tumour (1 of 1; 100%). One Leydig cell tumour showed equivocal staining (multifocal weak expression).ConclusionsOverall, PRKAR1A loss is both sensitive (93%) and highly specific (97%) for the diagnosis of LCCSCT. PRKAR1A loss may aid its diagnosis, particularly in sporadic cases and those that are the first presentation of Carney complex.
Poroelastic Attributes: A Real-time Determinant Membrane Nanorheology for Receptor Dependent Endocytosis of Targeted Gold Nanoparticles
Bhattacharya, Santanu , Bhattacharya, Santanu , Kulkarni, Tanmay , Mukhopadhyay, Debabrata

Mayo Clinic

No container title available | November 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1061474/v1 Get It

Abstract BackgroundEfficacy of targeted drug delivery using nanoparticles relies on several factors including the uptake mechanisms such as phagocytosis, macropinocytosis, micropinocytosis and receptor mediated endocytosis. These mechanisms have been studied with respect to the alteration in signaling mechanisms, cellular morphology, and linear nanomechanical properties (NMPs). Commonly employed classical contact mechanics models to address cellular NMPs fail to address mesh like structure consisting of bilayer lipids and proteins of cell membrane. To overcome this technical challenge, we employed poroelastic model which accounts for the biphasic nature of cells including their porous behavior exhibiting both solid like (fluid storage) and liquid like (fluid dissipate) behavior ResultsIn this study, we employed atomic force microscopy to monitor the influence of surface engineering of gold nanoparticles (GNPs) to the alteration of nonlinear NMPs such as drained Poisson’s ratio, effective shear stress, diffusion constant and pore dimensions of cell membranes during their uptake. Herein, we used pancreatic cancer (PDAC) cell lines including Panc1, AsPC-1 and endothelial cell HUVECs to understand the receptor-dependent and -independent endocytosis of two different GNPs derived using plectin-1 targeting peptide (PTP-GNP) and corresponding scrambled peptide (sPEP-GNP). Compared to untreated cells, in case of receptor dependent endocytosis of PTP-GNPs diffusion coefficient altered ~1264-fold and ~1530-fold and pore size altered ~320-fold and ~260-fold in Panc1 and AsPC-1 cells respectively. Whereas for receptor independent mechanisms, we observed modest alteration in diffusion coefficient and pore size, in these cells compared to untreated cells. Effective shear stress corresponding to 7.38±0.15 kPa and 20.49±0.39 kPa in PTP-GNP treatment in Panc1 and AsPC-1, respectively was significantly more than that for sPEP-GNP. These results demonstrate that with temporal recruitment of plectin-1 during receptor mediated endocytosis affects the poroelastic attributes of the membrane. ConclusionThis study confirms that nonlinear NMPs of cell membrane are directly associated with the uptake mechanism of nanoparticles and can provide promising insights of the nature of endocytosis mechanism involved for organ specific drug delivery using nanoparticles. Hence, nanomechanical analysis of cell membrane es using this noninvasive, label-free and live-cell analytical tool can therefore be instrumental to evaluate therapeutic benefit of nanoformulations.
Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms
He, Rong , Rech, Karen L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1305-1311

10.6004/jnccn.2021.7098 | PMID 34781270 Get It

Histiocytic neoplasms, including Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), and Rosai-Dorfman disease (RDD), present a diagnostic challenge due to nonspecific fibroinflammatory infiltrates and a diverse clinical presentation. The pathologist can play a key role in classification of these disorders through multidisciplinary collaboration and correlation of pathologic features with clinical and radiologic findings. The histopathologic differential diagnosis is broad, requiring knowledge of the possible diagnoses at each specific anatomic site, and a careful assessment to exclude other inflammatory and neoplastic disorders. An immunohistochemistry panel including CD163, CD1a, langerin, S100, Factor XIIIa, OCT2, and BRAF V600E can provide definitive diagnosis in LCH and RDD, whereas ECD requires classic clinical features as well as confirmation of an activating MAPK pathway mutation by genetic studies.
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Jacobsen, Eric D. , Baiocchi, Robert A. , Buhtoiarov, Ilia N. , Butler, Erin , Goodman, Aaron M. , Gratzinger, Dita , Higman, Meghan A., Hogarty, Michael D. , Jankú, Filip , Raldow, Anne C., Stefanovic, Alexandra, Tantravahi, Srinivas K. , Walkovich, Kelly, Bergman, Mary Anne, Darlow, Susan, Go, Ronald S. , Butler, Erin B. , Campbell, Patrick , Coulter, Donald W. , Diamond, Eli L. , Flagg, Aron , Goyal, Gaurav , Hendrie, Paul C. , Karmali, Reem , Morgan, David , Raldow, Ann C. , Zhang, Ling

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1277-1303

10.6004/jnccn.2021.0053 | PMID 34781268 Get It

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review
Asatryan, Babken , Landstrom, Andrew P. , Khanji, Mohammed Y , Odening, Katja E. , Gelzer, Anna R. , Semsarian, Christopher , Owens, Anjali , Chahal, C. Anwar A. , Asimaki, Angeliki , Landstrom, Andrew P , Khanji, Mohammed Yunus , Odening, Katja E , Gelzer, Anna R , Reichlin, Tobias , Chahal, Choudhary Anwar A , Asatryan, Babken , Asimaki, Angeliki , Cooper, Leslie T. , Marchlinski, Francis E.

Mayo Clinic

Circulation | November 15, 2021 | Volume: 144 | Issue: 20 | Pages: 1646-1655

10.1161/circulationaha.121.055890 | PMID 34780255 Get It

Arrhythmogenic cardiomyopathy (ACM) is a primary disease of the myocardium, predominantly caused by genetic defects in proteins of the cardiac intercalated disc, particularly, desmosomes. Transmission is mostly autosomal dominant with incomplete penetrance. ACM also has wide phenotype variability, ranging from premature ventricular contractions to sudden cardiac death and heart failure. Among other drivers and modulators of phenotype, inflammation in response to viral infection and immune triggers have been postulated to be an aggravator of cardiac myocyte damage and necrosis. This theory is supported by multiple pieces of evidence, including the presence of inflammatory infiltrates in more than two-thirds of ACM hearts, detection of different cardiotropic viruses in sporadic cases of ACM, the fact that patients with ACM often fulfill the histological criteria of active myocarditis, and the abundance of anti–desmoglein-2, antiheart, and anti-intercalated disk autoantibodies in patients with arrhythmogenic right ventricular cardiomyopathy. In keeping with the frequent familial occurrence of ACM, it has been proposed that, in addition to genetic predisposition to progressive myocardial damage, a heritable susceptibility to viral infections and immune reactions may explain familial clustering of ACM. Moreover, considerable in vitro and in vivo evidence implicates activated inflammatory signaling in ACM. Although the role of inflammation/immune response in ACM is not entirely clear, inflammation as a driver of phenotype and a potential target for mechanism-based therapy warrants further research. This review discusses the present evidence supporting the role of inflammatory and immune responses in ACM pathogenesis and proposes opportunities for translational and clinical investigation.
Tafamidis and Quality of Life in People With Transthyretin Amyloid Cardiomyopathy in the Study ATTR-ACT: A Plain Language Summary
Hanna, Mazen , Grogan, Martha , Stewart, Michelle, Gundapaneni, Balarama, Sultan, Marla B. , Damy, Thibaud , Maurer, Matthew J.

Mayo Clinic

Future Cardiology | November 15, 2021 | Volume: 18 | Issue: 3 | Pages: 165-172

10.2217/fca-2021-0095 | PMID 34779246 Get It

Faculty Opinions recommendation of Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
Padmanabhan, Anand

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740628143.793589561 Get It